Arvinas Holding Company (ARVN)
NASDAQ:ARVN
Want to see ARVN full AI Analyst Report?
ARVN Stock Chart & Stats
$11.00
$0.30(1.54%)
At close: 4:00 PM EST
$11.00
$0.30(1.54%)
Day’s Range― - ―
52-Week Range$5.90 - $14.51
Previous CloseN/A
Volume216.17K
Average Volume (3M)860.37K
Market Cap
$633.21M
Enterprise Value$493.70M
Total Cash (Recent Filing)$685.40M
Total Debt (Recent Filing)$8.50M
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Aug 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding63,961,000
10 Day Avg. Volume757,345
30 Day Avg. Volume860,366
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)1.77
Price to Sales (P/S)2.93
P/FCF Ratio-2.79
Enterprise Value/Market Cap0.78
Enterprise Value/Revenue1.88
Enterprise Value/Gross Profit1.89
Enterprise Value/Ebitda-5.07
Forecast
1Y Price Target
$16.45Price Target Upside49.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)-3.37
Revenue Forecast (FY)$93.17M
Bulls Say, Bears Say
Bulls Say
Clinical Biomarker EfficacyARV-102 produced consistent reductions in cerebrospinal fluid and blood markers tied to LRRK2 activity and neuroinflammation, providing human proof-of-concept for brain target engagement and pathway modulation.
Clinical Development MomentumPhase 1 programs for ARV-806 and ARV-102 enrolled quickly and showed tolerable safety profiles, accelerating clinical data generation that could drive revaluation as programs advance.
Differentiated Mechanism And Pipeline BreadthThe PROTAC degrader approach that removes the entire LRRK2 protein and ARV-806's targeting of both active and inactive KRAS forms create mechanistic differentiation versus kinase inhibitors and broaden potential indications across neurodegeneration and oncology.
Bears Say
Clinical Benefit UncertaintyBiomarker improvements with ARV-102 have not yet been shown to produce meaningful functional benefit in patients, leaving a central efficacy risk for later-stage trials.
Market Size And Competitive PressureIf use of the therapy is restricted to patients with a specific genetic form of disease, the addressable patient population may be small and competing programs in broader populations could limit commercial uptake.
Pulmonary Safety RiskLRRK2-targeted therapies have known associations with lung effects, so longer-duration pulmonary monitoring is required and emerging lung toxicity could impose development hurdles.
Arvinas Holding Company News
ARVN FAQ
What was Arvinas Holding Company’s price range in the past 12 months?
Arvinas Holding Company lowest stock price was $5.90 and its highest was $14.51 in the past 12 months.
What is Arvinas Holding Company’s market cap?
Arvinas Holding Company’s market cap is $633.21M.
When is Arvinas Holding Company’s upcoming earnings report date?
Arvinas Holding Company’s upcoming earnings report date is Aug 11, 2026 which is in 102 days.
How were Arvinas Holding Company’s earnings last quarter?
Currently, no data Available
Is Arvinas Holding Company overvalued?
According to Wall Street analysts Arvinas Holding Company’s price is currently Undervalued.
Does Arvinas Holding Company pay dividends?
Arvinas Holding Company does not currently pay dividends.
What is Arvinas Holding Company’s EPS estimate?
Arvinas Holding Company’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Arvinas Holding Company have?
Arvinas Holding Company has 63,961,000 shares outstanding.
What happened to Arvinas Holding Company’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Arvinas Holding Company?
Currently, no hedge funds are holding shares in ARVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arvinas Holding Company Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.45 (49.59% Upside)
$16.45 (49.59% Upside)
Blogger Sentiment
Bullish
ARVN Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 83.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $566.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.90%
12-Months-Change
Fundamentals
Return on Equity
-14.25%
Trailing 12-Months
Asset Growth
-34.22%
Trailing 12-Months
Company Description
Arvinas Holding Company
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
ARVN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed strong scientific and clinical momentum—multiple programs advancing, encouraging early biomarker and preclinical signals, and disciplined cost reductions—while simultaneously revealing material financial pressure from a steep decline in cash and a large quarter-over-quarter revenue drop. The company maintained guidance for cash runway into 2028 and emphasized partner discussions, but the balance sheet tightening and competitive landscape create meaningful execution and financing risk alongside the positive clinical developments.View all ARVN earnings summariesARVN Stock 12 Month Forecast
Average Price Target
$16.45
▲(49.59% Upside)
Technical Analysis
AnaptysBio
―
Meiragtx Holdings
―
Compass Therapeutics
―
Olema Pharmaceuticals
―
Bicara Therapeutics Inc.
―
Ownership Overview
3.73% Insiders
18.53% Mutual Funds
1.14% Other Institutional Investors
63.77% Public Companies and
Individual Investors